Answer: Deeply concerned about the increasingly important role that software was playing in the development
and marketing of toys, Mattel may have been frantic to acquire a leading maker of software for toys to remain
2. Was this related or unrelated diversification for Mattel? How might this have influenced the outcome?
Answer: The Learning Company represented the application of software to the toy industry; however, it was
3. Why could Gores Technology do in a matter of weeks what the behemoth toy company, Mattel, could not
do?
Answer: Gores was in the business of turning around companies. They knew what to do and appreciated the
need for speed. Gores also exhibited the ability that eluded Mattel to make quick decisions. Mattel may have
Pfizer Acquires Pharmacia to Solidify Its Top Position
In 1990, the European and U.S. markets were about the same size; by 2000, the U.S. market had grown to twice that of
the European market. This rapid growth in the U.S. market propelled American companies to ever increasing market
share positions. In particular, Pfizer moved from 14th in terms of market share in 1990 to the top spot in 2000. With the
acquisition of Pharmacia in 2002, Pfizer’s global market share increased by three percentage points to 11%. The top ten
drug firms controlled more than 50 percent of the global market, up from 22 percent in 1990.
Pfizer and Pharmacia knew each other well. They had been in a partnership since 1998 to market the world’s leading
arthritis medicine and the 7th largest selling drug globally in terms of annual sales in Celebrex. The companies were
continuing the partnership with 2nd generation drugs such as Bextra launched in the spring of 2002. For Pharmacia’s
management, the potential for combining with Pfizer represented a way for Pharmacia and its shareholders to participate
in the biggest and fastest growing company in the industry, a firm more capable of bringing more products to market
than any other.
The deal offered substantial cost savings, immediate access to new products and markets, and access to a number of
potentially new blockbuster drugs. Projected cost savings are $1.4 billion in 2003, $2.2 billion in 2004, and $2.5 billion
in 2005 and thereafter. Moreover, Pfizer gained access to four more drug lines with annual revenue of more than $1
billion each, whose patents extend through 2010. That gives Pfizer, a portfolio, including its own, of 12 blockbuster